世界の抗体ヒット創出および探索市場 - 分析と予測（2023年～2032年）

世界の抗体ヒット創出および探索の市場規模は、慢性疾患の増加、抗体工学の進歩、研究開発投資の増加などにより促進されています。

さらに、個別化医療に対する需要の高まりやバイオ医薬品産業の拡大も、市場の好循環に寄与しています。

当レポートでは、世界の抗体ヒット創出および探索市場について調査し、市場の概要とともに、用途別、技術別、抗体タイプ別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

調査範囲

調査手法

第1章 市場

• 世界市場の展望
• 製品の定義
• 包含基準と除外基準
• 主な調査結果
• 前提条件と制限事項
• 世界市場シナリオ
• 業界の展望
• 主要な動向
• 特許分析
• 製品のベンチマーク
• COVID-19が世界の抗体ヒット創出および探索市場に与える影響
• 市場規模への影響
• 市場参入障壁と機会
• ビジネスダイナミクス
• 影響分析

第2章 世界の抗体ヒット創出および探索市場（技術別）

• 機会の評価
• 成長シェアマトリックス

第3章 世界の抗体ヒット創出および探索市場（抗体タイプ別）

• 機会の評価
• 成長シェアマトリックス

第4章 世界の抗体ヒット創出および探索市場（用途別）

• 機会の評価
• 成長シェアマトリックス

第5章 地域

• 北米の抗体ヒット創出および探索市場
• 欧州の抗体ヒット創出および探索市場
• アジア太平洋の抗体ヒット創出および探索市場
• ラテンアメリカの抗体ヒット創出および探索市場
• その他の地域の抗体ヒット創出および探索市場

第6章 市場

• 競合ベンチマーキングと企業プロファイル
• 競合情勢
  • 主要な戦略と展開
• 企業プロファイル
  • F. Hoffmann-La Roche Ltd.
  • AbbVie
  • Pfizer
  • AstraZeneca
  • Novartis
  • Eli Lilly
  • WuXi AppTec
  • Charles River Laboratories
  • Syngenta
  • BioLegend
  • Creative Biolabs
  • Eurofins CDMO
  • AbCellera
  • MorphoSys
  • Evelo Biosciences
  • Icos Therapeutics
  • Argenx
  • Kymab
  • Alnylam Pharmaceuticals
  • SAb Biotherapeutics
  • その他の企業

The Global Antibody Hit Generation and Screening Market report offers a detailed and comprehensive analysis of the industry, providing valuable insights into market trends, growth drivers, challenges, and future opportunities. The report covers key segments, competitive landscape, and emerging technologies, offering stakeholders a holistic view of the global market.

The study identifies and analyzes the primary drivers influencing market growth. Factors such as the increasing prevalence of chronic diseases, advancements in antibody engineering, and rising investments in research and development are explored. Additionally, the growing demand for personalized medicine and the expanding biopharmaceutical industry contribute to the positive trajectory of the market.

Market Segmentation:

Segmentation 1: by Application

• Cancer
• Autoimmune diseases
• Infectious diseases

Segmentation 2: by Technologies

• Hit Generation
• Phage display
• Yeast display
• Ribosome display
• B-cell hybridoma technology
• Computational tools
• Screening

Segmentation 3: by Antibody Type

• Humanized Antibody
• Human Antibody
• Chimeric Antibody
• Murine Antibody

Segmentation 4: by Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Rest-of-the-World

Some prominent players established in this market are:

• Creative Biolabs
• F. Hoffmann-La Roche Ltd.
• WuXi AppTec
• Icos Therapeutics

Key Questions Answered:

• What are the major market drivers, challenges and opportunities in the global antibody hit generation and screening market?
• How the antibody hit generation and screening market evolves and what did is its scope in the future?
• How will each segment of the global antibody hit generation and screening market grow during the forecast period?
• How will the industry evolve during the forecast period?
• What are the key developmental strategies implemented by the key players to stand out in this market?

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1. Market

• 1.1. Global Market Outlook
• 1.2. Product Definition
• 1.3. Inclusion and Exclusion Criteria
• 1.4. Key Findings
• 1.5. Assumptions and Limitations
• 1.6. Global Market Scenario
  • 1.6.1. Realistic Scenario
  • 1.6.2. Optimistic Scenario
  • 1.6.3. Pessimistic Scenario
• 1.7. Industry Outlook
• 1.8. Key Trends
• 1.9. Patent Analysis
  • 1.9.1. Awaited Technological Developments
  • 1.9.2. Patent Filing Trend (by Country/Cluster)
  • 1.9.3. Patent Filing Trend (by Year)
• 1.10. Product Benchmarking
• 1.11. Impact of COVID-19 on Global Antibody Hit Generation and Screening Market
• 1.12. Impact on Market Size
  • 1.12.1. Pre-COVID-19 Phase
  • 1.12.2. During-COVID-19 Phase
  • 1.12.3. Post-COVID-19 Phase
• 1.13. Market Entry Barriers and Opportunities
• 1.14. Business Dynamics
• 1.15. Impact Analysis
  • 1.15.1. Business Drivers
  • 1.15.2. Business Restraints
  • 1.15.3. Business Opportunities

2. Global Antibody Hit Generation and Screening Market (by Technologies)

• 2.1. Opportunity Assessment
• 2.2. Growth Share Matrix
  • 2.2.1. Hit Generation
  • 2.2.2. Phage display
  • 2.2.3. Yeast display
  • 2.2.4. Ribosome display
  • 2.2.5. B-cell hybridoma technology
  • 2.2.6. Computational tools
  • 2.2.7. Screening

3. Global Antibody Hit Generation and Screening Market (by Antibody Type)

• 3.1. Opportunity Assessment
• 3.2. Growth Share Matrix
  • 3.2.1. Humanized Antibody
  • 3.2.2. Human Antibody
  • 3.2.3. Chimeric Antibody
  • 3.2.4. Murine Antibody

4. Global Antibody Hit Generation and Screening Market (by Applications)

• 4.1. Opportunity Assessment
• 4.2. Growth Share Matrix
  • 4.2.1. Cancer
  • 4.2.2. Autoimmune diseases
  • 4.2.3. Infectious diseases

5. Region

• 5.1. North America Antibody Hit Generation and Screening Market
• 5.2. Key Findings and Opportunity Assessment
• 5.3. Regulatory Framework
• 5.4. Market Dynamics
  • 5.4.1. Impact Analysis
• 5.5. Sizing and Forecast Analysis
  • 5.5.1. North America Antibody Hit Generation and Screening Market (by Technologies)
  • 5.5.2. North America Antibody Hit Generation and Screening Market (by Country)
    • 5.5.2.1.1. U.S.
    • 5.5.2.1.2. Canada
• 5.6. Europe Antibody Hit Generation and Screening Market
• 5.7. Key Findings and Opportunity Assessment
• 5.8. Regulatory Framework
• 5.9. Market Dynamics
  • 5.9.1. Impact Analysis
• 5.10. Sizing and Forecast Analysis
  • 5.10.1. Europe Antibody Hit Generation and Screening Market (by Technologies)
  • 5.10.2. Europe Antibody Hit Generation and Screening Market (by Country)
    • 5.10.2.1.1. Germany
    • 5.10.2.1.2. France
    • 5.10.2.1.3. U.K.
    • 5.10.2.1.4. Italy
    • 5.10.2.1.5. Spain
    • 5.10.2.1.6. Rest-of-Europe
• 5.11. Asia-Pacific Antibody Hit Generation and Screening Market
• 5.12. Key Findings and Opportunity Assessment
• 5.13. Regulatory Framework
• 5.14. Market Dynamics
  • 5.14.1. Impact Analysis
• 5.15. Sizing and Forecast Analysis
  • 5.15.1. Asia-Pacific Antibody Hit Generation and Screening Market (by Technologies)
  • 5.15.2. Asia-Pacific Antibody Hit Generation and Screening Market (by Country)
    • 5.15.2.1.1. Japan
    • 5.15.2.1.2. China
    • 5.15.2.1.3. Australia
    • 5.15.2.1.4. India
    • 5.15.2.1.5. South Korea
    • 5.15.2.1.6. Rest-of-Asia-Pacific
• 5.16. Latin America Antibody Hit Generation and Screening Market
• 5.17. Key Findings and Opportunity Assessment
• 5.18. Regulatory Framework
• 5.19. Market Dynamics
  • 5.19.1. Impact Analysis
• 5.20. Sizing and Forecast Analysis
  • 5.20.1. Latin America Antibody Hit Generation and Screening Market (by Technologies)
  • 5.20.2. Latin America Antibody Hit Generation and Screening Market (by Country)
    • 5.20.2.1.1. Brazil
    • 5.20.2.1.2. Mexico
    • 5.20.2.1.3. Rest-of-Latin America
• 5.21. Rest-of-the-World Antibody Hit Generation and Screening Market
• 5.22. Key Findings and Opportunity Assessment
• 5.23. Regulatory Framework
• 5.24. Market Dynamics
  • 5.24.1. Impact Analysis
• 5.25. Sizing and Forecast Analysis
  • 5.25.1. Rest-of-the-World Antibody Hit Generation and Screening Market (by Technologies)

6. Markets

• 6.1. Competitive Benchmarking and Company Profiles
• 6.2. Competitive Landscape
  • 6.2.1. Key Strategies and Developments
    • 6.2.1.1.1. Partnerships, Alliances, and Business Expansion
    • 6.2.1.1.2. Funding Activities
    • 6.2.1.1.3. New Offerings
    • 6.2.1.1.4. Mergers and Acquisitions
    • 6.2.1.1.5. Regulatory and Legal Activities
• 6.3. Company Profiles
  • 6.3.1. F. Hoffmann-La Roche Ltd.
  • 6.3.2. Company Overview
  • 6.3.3. Product Portfolio
  • 6.3.4. Financials
  • 6.3.5. Recent Developments
  • 6.3.6. Analyst Perspective
  • 6.3.7. AbbVie
  • 6.3.8. Pfizer
  • 6.3.9. AstraZeneca
  • 6.3.10. Novartis
  • 6.3.11. Eli Lilly
  • 6.3.12. WuXi AppTec
  • 6.3.13. Charles River Laboratories
  • 6.3.14. Syngenta
  • 6.3.15. BioLegend
  • 6.3.16. Creative Biolabs
  • 6.3.17. Eurofins CDMO
  • 6.3.18. AbCellera
  • 6.3.19. MorphoSys
  • 6.3.20. Evelo Biosciences
  • 6.3.21. Icos Therapeutics
  • 6.3.22. Argenx
  • 6.3.23. Kymab
  • 6.3.24. Alnylam Pharmaceuticals
  • 6.3.25. SAb Biotherapeutics
  • 6.3.26. Other Companies

* Financials are provided for the public companies only